Global Protein Glutamine Gamma Glutamyltransferase 2 Market Size By Type (CAT-5571, ERW-1041E), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Protein Glutamine Gamma Glutamyltransferase 2 Market was valued at USD 712.4 million in 2023 and is expected to reach USD 1.32 billion by 2031, growing at a CAGR of 8.1% during the forecast period of 2023–2031. This growth is driven by the enzyme's expanding applications in tissue transglutaminase testing, celiac disease diagnostics, and cancer biomarker development. Rising demand in precision diagnostics, coupled with increasing research into autoimmune and neurodegenerative diseases, is propelling the adoption of Protein Glutamine Gamma Glutamyltransferase 2 across the pharmaceutical and biotechnology sectors.

Drivers:

1. Increasing Prevalence of Autoimmune Disorders:

With celiac disease and other autoimmune conditions becoming more prevalent, the demand for protein glutamine gamma-glutamyltransferase 2 as a biomarker has surged due to its specificity and diagnostic reliability.

2. Expanding Role in Cancer Diagnostics and Therapeutics:

The enzyme plays a pivotal role in tumor progression and has gained attention as a target for anticancer drug development, boosting its importance in oncology R&D.

3. Growth in Precision Medicine and Personalized Diagnostics:

As personalized healthcare advances, the need for highly specific molecular markers like Protein Glutamine Gamma Glutamyltransferase 2 increases, aiding in early and accurate diagnosis.

Restraints:

1. High Cost of Diagnostic Testing Kits and Research Tools:

The cost associated with high-sensitivity diagnostic kits and proprietary research reagents limits accessibility, especially in lower-income regions.

2. Limited Awareness Among Primary Healthcare Providers:

Despite its clinical relevance, the enzyme remains underutilized in primary care settings due to limited awareness and training regarding its diagnostic capabilities.

Opportunity:

1. Emerging Applications in Neurological Disorders:

New research is exploring the enzyme’s involvement in neuroinflammation and neurodegenerative diseases such as Alzheimer’s and Parkinson’s, unlocking potential for novel diagnostics and therapeutics.

2. Adoption in Biomarker Discovery Platforms:

The integration of protein glutamine gamma-glutamyltransferase 2 in multiplex biomarker platforms creates opportunities for broader usage in laboratory diagnostics and pharmaceutical R&D.

Market by System Type Insights:

The Enzyme Assay Kits segment held the largest share in 2023, driven by widespread use in celiac disease diagnostics and laboratory research. These kits offer high sensitivity, ease of use, and compatibility with automation systems. However, the Antibody-based Detection Systems segment is projected to grow at the fastest rate during the forecast period, due to increasing application in immunohistochemistry and therapeutic monitoring.

Market by End-use Insights:

Hospitals and Diagnostic Laboratories dominated the market in 2023, accounting for more than 45% of the revenue share. These facilities rely heavily on accurate and early diagnostics, particularly for autoimmune and gastrointestinal diseases. Meanwhile, the Pharmaceutical & Biotechnology Companies segment is expected to exhibit strong growth due to expanding drug discovery initiatives and translational research involving the enzyme.

Market by Regional Insights:

North America led the global market in 2023, driven by advanced healthcare infrastructure, early adoption of precision diagnostics, and a strong presence of key diagnostic companies. Asia-Pacific is anticipated to witness the highest CAGR during the forecast period due to growing healthcare expenditure, increased awareness of autoimmune diseases, and rapid development in molecular diagnostics across countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global Protein Glutamine Gamma Glutamyltransferase 2 Market include Thermo Fisher Scientific Inc., Abcam plc, Bio-Rad Laboratories, Merck KGaA, Enzo Life Sciences, OriGene Technologies Inc., GenScript Biotech Corporation, and Creative Enzymes. These companies focus on developing advanced assay platforms, strategic partnerships, and regional expansion to gain a competitive edge.

Scope of Work – Global Protein Glutamine Gamma Glutamyltransferase 2 Market

Report Metric Details

Market Size (2023) USD 712.4 million

Projected Market Size (2031) USD 1.32 billion

CAGR (2023–2031) 8.1%

Market Segments By System Type (Enzyme Assay Kits, Antibody-based Detection), End-use

Growth Drivers Rise in autoimmune diseases, role in cancer diagnostics, precision medicine

Opportunities Neurodegenerative disorder diagnostics, integration in biomarker platforms

Key Market Developments:

July 2023 – Abcam plc launched a next-generation antibody panel targeting tissue transglutaminase 2 for enhanced detection in immunofluorescence and ELISA applications.

October 2023 – Thermo Fisher Scientific introduced high-throughput enzyme assay kits optimized for translational and clinical research involving tTG2.

February 2024 – Bio-Rad Laboratories collaborated with a European research consortium to explore tTG2's role as a biomarker in early-stage neurodegenerative disorders.

FAQs:

1) What is the current market size of the Global Protein Glutamine Gamma Glutamyltransferase 2 Market?

The market was valued at USD 712.4 million in 2023.

2) What is the major growth driver of the Global Protein Glutamine Gamma Glutamyltransferase 2 Market?

The rising prevalence of autoimmune diseases and its growing use as a cancer biomarker are key drivers.

3) Which is the largest region during the forecast period in the Global Protein Glutamine Gamma Glutamyltransferase 2 Market?

North America is expected to remain the largest regional market.

4) Which segment accounted for the largest market share in the Global Protein Glutamine Gamma Glutamyltransferase 2 Market?

The Enzyme Assay Kits segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Protein Glutamine Gamma Glutamyltransferase 2 Market?

Thermo Fisher Scientific, Abcam, Bio-Rad Laboratories, Merck KGaA, and GenScript Biotech are among the major players.